Skip to main content
. 2019 Mar 6;3:PO.18.00211. doi: 10.1200/PO.18.00211

FIG 5.

FIG 5.

Liquid biopsy mutation correlation to response rate as calculated by change in radiologic response (RECIST 1.1) versus change in mutation molecules, representative of tumor mutation burden, after first-line platinum-based chemotherapy in an unselected cohort with advanced non–small-cell lung cancer (n = 31). Data from 20 patients are shown; others lacked baseline genomic alterations or RECIST data. (*) Two data points, with overlapping data. ctDNA, circulating tumor DNA. D42, day 42.